Evidence map›Paper›PMID 39101162›Full record

ArticleDiabetology international2024

Exosomal UMOD gene expression and urinary uromodulin level as early noninvasive diagnostic biomarkers for diabetic nephropathy in type 2 diabetic patients.

Shaimaa I Barr, Sahar S Bessa, Tarek M Mohamed, Eman M Abd El-Azeem

Abstract read
In one paragraph

Article in Diabetology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026
    Review
  6. Endocrine regulation of uromodulin in aging.Frontiers in endocrinology · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Urinary exosomes as promising biomarkers for early kidney disease detection.American journal of clinical and experimental urology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shaimaa I BarrBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.ORCID 0000-0002-9648-4526
Sahar S BessaInternal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tarek M MohamedBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Eman M Abd El-AzeemBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. Exosomes are promising biomarkers for disease diagnosis and uromodulin is a kidney-specific protein. So, this study was designed to investigate the change in the gene expression of urinary exosomal uromodulin mRNA and urinary uromodulin level and determine the diagnostic potential of these noninvasive biomarkers in the early stage of diabetic nephropathy in type 2 diabetic patients. Method: This study included 100 participants; urinary exosomes were isolated using polyethylene glycol (PEG). Gene expression of exosomal uromodulin mRNA was determined by quantitative real-time polymerase chain reaction (q-RT-PCR). The urinary uromodulin levels were determined by an enzyme-linked immunosorbent assay (ELISA). Result: In this study, the gene expression of exosomal uromodulin ( Conclusion: Urinary exosomal mRNA of

Indexed as

Diabetic nephropathyUrinary exosomesUrinary uromodulinUromodulin mRNA

Identifiers

PMID39101162
PMCPMC11291796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.